Application covers a method to identify and purify undifferentiated stem cells from solid breast carcinomas that are resistant to traditional therapeutics.
NextGen Bioscience has obtained use, commercialization, and ownership rights of Oxon Life Science’s patent application related to cancer stem cells.
The application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are usually resistant to conventional therapies, the companies explain.
“Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies,” notes NextGen CEO, Konstantinos Kardiasmenos.
